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NOX1 and DUOX2 are the predominant source of intestinal
epithelial ROS. Here we identify novel NOX1 and DUOX2
variants associated with VEOIBD that result in reduced ROS
production, Paneth cell metaplasia and defective host
resistance to C. jejuni.*Authors contributed equally to the study; §Participant in the Inter-
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http://dx.doi.org/10.1016/j.jcmgh.2015.06.005BACKGROUND & AIMS: Defects in intestinal innate defense
systems predispose patients to inﬂammatory bowel disease
(IBD). Reactive oxygen species (ROS) generated by
nicotinamide-adenine dinucleotide phosphate (NADPH) oxi-
dases in the mucosal barrier maintain gut homeostasis and
defend against pathogenic attack. We hypothesized that mo-
lecular genetic defects in intestinal NADPH oxidases might be
present in children with IBD.
METHODS: After targeted exome sequencing of epithelial NADPH
oxidases NOX1 and DUOX2 on 59 children with very early onset
inﬂammatory bowel disease (VEOIBD), the identiﬁed mutations
were validated using Sanger Sequencing. A structural analysis of
NOX1 and DUOX2 variants was performed by homology in silico
modeling. The functional characterization included ROS genera-
tion in model cell lines and in in vivo transduced murine crypts,
protein expression, intracellular localization, and cell-based
infection studies with the enteric pathogens Campylobacter
jejuni and enteropathogenic Escherichia coli.
RESULTS: We identiﬁed missense mutations in NOX1
(c.988G>A, p.Pro330Ser; c.967G>A, p.Asp360Asn) and DUOX2
(c.4474G>A, p.Arg1211Cys; c.3631C>T, p.Arg1492Cys) in 5 of209 VEOIBD patients. The NOX1 p.Asp360Asn variant was
replicated in a male Ashkenazi Jewish ulcerative colitis cohort.
Patients with both NOX1 and DUOX2 variants showed
abnormal Paneth cell metaplasia. All NOX1 and DUOX2 variants
showed reduced ROS production compared with wild-type
enzymes. Despite appropriate cellular localization and compa-
rable pathogen-stimulated translocation of altered oxidases,
cells harboring NOX1 or DUOX2 variants had defective host
resistance to infection with C. jejuni.
CONCLUSIONS: This study identiﬁes the ﬁrst inactivating
missense variants in NOX1 and DUOX2 associated with VEOIBD.
Defective ROS production from intestinal epithelial cells
constitutes a risk factor for developing VEOIBD. (Cell Mol
490 Hayes et al Cellular and Molecular Gastroenterology and Hepatology Vol. 1, No. 5Gastroenterol Hepatol 2015;1:489–502; http://dx.doi.org/
10.1016/j.jcmgh.2015.06.005)
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nﬂammatory bowel disease (IBD), a complex diseaseIassociated with genetic predisposition and environ-
mental factors, is characterized by recurrent intestinal
inﬂammation and microbial dysbiosis. Genomewide associ-
ation studies link adult IBD to alterations in genes involved
in host-microbe interactions.1,2 Nicotinamide adenine
dinucleotide phosphate (NADPH) oxidase-generated reac-
tive oxygen species (ROS) are intrinsic to the antimicrobial
host defense system of professional phagocytes. Defective
ROS production in patients with chronic granulomatous
disease (CGD), a rare genetic disorder caused by inactivating
alterations of genes required for formation of the penulti-
mate phagocyte oxidase complex (CYBB, CYBA, NCF1, NCF2,
NCF4), confers susceptibility to life-threatening bacterial
and fungal infections.3 Up to 40% of CGD patients develop
inﬂammatory colitis that mimics Crohn’s disease.4 Genetic
variants in NCF4 and NCF2 that lead to partial attenuation in
phagocyte oxidase (NADPH oxidase 2, NOX2) function
without causing CGD have been associated with adult and
very early onset IBD (VEOIBD).5,6 We have recently shown
that single-nucleotide polymorphisms (SNPs) and rare
hypomorphic variants in all components of the NOX2
NADPH oxidase complex are associated with VEOIBD.7
A role for ROS production by intestinal epithelial cells in
mucosal barrier function and intestinal homeostasis is just
emerging.8 The predominant sources of ROS in the lining of
the gastrointestinal tract are the NADPH oxidases NOX1
(NADPH oxidase 1) and DUOX2 (dual oxidase 2), with NOX1
expression restricted mainly to colon, caecum, and ileum,
whereas DUOX2 can be found in all segments of the gut.9
NOX1 and DUOX2 are the catalytic subunits of multimeric,
membrane-bound enzymes that generate upon stimulation
superoxide and hydrogen peroxide by transfer of electrons
from NADPH to molecular oxygen. We10 and others11–13
have reported NOX1/DUOX2-mediated ROS production in
the intestine and its effect on bacterial pathogenicity and
barrier integrity. Here, we describe the identiﬁcation and
characterization of missense mutations in NOX1
(NM_007052.4, location Xq22) and in DUOX2 (NG_016992,
location 15q15.3) in patients diagnosed with VEOIBD.Materials and Methods
Study Design
All results are presented according to the STrengthening
the REporting of Genetic Association Studies (STREGA)
guidelines.14 Fifty-nine IBD patients diagnosed under the
age of 6 years were sequenced for NOX1 and DUOX2 by
targeted exome sequencing using Agilent SureSelect
target enrichment and sequencing (Agilent Technologies,
Santa Clara, CA) on the Illumina HiSeq 2000/2500 (Illumina,
San Diego, CA) with exon primer and sequencingprotocols designed by the Beckman Coulter Genomics
(beckmangenomics.com; Beckman Coulter, Brea, CA) as
described previously elsewhere.15 Sanger sequencing was
used to verify all genetic defects identiﬁed using targeted
sequencing of the NOX1 and DUOX2 genes at the Centre for
Applied Genomics (TCAG; http://www.tcag.ca; Hospital for
Sick Children, Toronto, ON, Canada).
Single-nucleotide and insertion/deletion (indel) variants
identiﬁed by targeted exome sequencing and validated by
Sanger sequencing were automatically scanned and manu-
ally veriﬁed. Furthermore, all variants were also validated
using Taqman performed by the Centre for Applied Geno-
mics, Hospital for Sick Children.15,16 Function and minor
allele frequency (MAF) were searched for using the National
Heart, Lung, and Blood Institute Exome Sequencing Project
(ESP) Exome Variant Server (http://evs.gs.washington.edu/
EVS/), the National Center for Biotechnology Information
dbSNP (http://www.ncbi.nlm.nih.gov/projects/SNP/), the
National Institute of Environmental Health Sciences FuncPred
(http://snpinfo.niehs.nih.gov/snpinfo/snpfunc.htm), Polyphen2
(http://genetics.bwh.harvard.edu/pph2/),17 SIFT (http://
sift.jcvi.org/),18 FastSNP (http://fastsnp.ibms.sinica.edu.tw/),19
Human Splicing Finder (http://www.umd.be/HSF/),20 and
pfSNP (http://pfs.nus.edu.sg/).21Setting
Patients included in the study were recruited from the
Inﬂammatory Bowel Disease Clinic at the Hospital from Sick
Children, University of Toronto. They were diagnosed with
VEOIBD between the years 1994 and 2012 and had a
conﬁrmed diagnosis of IBD before the age of 6 years.
Although there is no consensus on the deﬁnition of VEOIBD,
we have used the stricter deﬁnition based on our recent
modiﬁcation (diagnosis <6 years of age)5,22,23 of the Paris
classiﬁcation.24 Our deﬁnition, which is more stringent and
includes more severe cases that are more likely to cause
monogenic forms of the disease, has been used to identify
risk variants in this age group. There were no exclusion
criteria for patients diagnosed with VEOIBD; however, pa-
tients with a known immunodeﬁciency or a clinical diag-
nosis of CGD were excluded because these patients were not
deﬁned as VEOIBD. The ﬁve identiﬁed patients were
screened and were found negative for pathogenic mutations
in IL10RA, IL10RB, IL10, XIAP, TTC7A, as well as genes
involved in CGD (RAC1/2, NCF1/2/4, and CYBB, CYBA)23,25
and NOD2 and ATG16L1 variants associated with IBD.Participants
This was a cohort study that examined the genetics of
VEOIBD patients. Fifty-ﬁve VEOIBD patients were recruited
from the Hospital for Sick Children, Toronto, Canada. A
second cohort of VEOIBD patients was recruited through
NEOPICS (www.NEOPICS.org). The replication cohort
comprised 1477 Crohn’s disease cases, 559 ulcerative colitis
cases, and 2614 healthy controls, all with genetically veri-
ﬁed Ashkenazi Jewish ancestry by principal components
analysis.
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we performed association testing using Fisher’s exact
method, stratiﬁed by gender in 297 male ulcerative colitis
(UC) cases, 262 female UC cases, 1708 male controls, and
906 female controls. Phenotypic information and DNA
samples were obtained from the study participants with
approval of the institutional review ethics board for IBD
genetic studies at the Hospital for Sick Children and Mount
Sinai Hospital Toronto.
Later onset UC cases were recruited through the
National Institute of Diabetes and Digestive and Kidney
Diseases Inﬂammatory Bowel Disease Genetics Consortium,
the Cedars-Sinai Medical Center IBD Center in California and
Mount Sinai Hospital in New York. Replication cohorts had
ethics board approval for genetic and phenotypic studies at
the individual institutions. Written informed consent was
obtained from all participants/parents.H&E and Periodic Acid–Schiff Staining in Patient
Biopsy Samples
Colonic biopsy samples were ﬁxed in 10% formaldehyde
without methanol and afterward embedded in parafﬁn. For
H&E staining, embedded parafﬁn tissues on slides were
deparafﬁnized with xylene and afterward rehydrated with
different percentages of ethanol. The slides were stained for
5 minutes with Meyer’s hematoxylin (Fisher Scientiﬁc, Fair
Lawn, NJ) for nuclei and counterstained with eosin-Y (Fisher
Scientiﬁc) for cytoplasm. Slides were mounted in Entellan
(EMD Millipore, Billerica, MA). Photographs were taken
using an epiﬂuorescence light microscope (Leica Micro-
systems, Buffalo Grove, IL) and adjusted for brightness,
contrast, and pixel size in Adobe Photoshop CS5 version
12.0 (Adobe System, San Jose, CA).Modeling and Docking Procedure
Three-dimensional (3D) models of C-terminal domains
of NOX1 and DUOX2 were generated using the homology
modeling program Modeller 9v11 (http://www.salilab.
org/modeller/).26 Blast of PDB was performed with the
NOX1 FAD-binding domain, and a combination of several
homologous structures served together with the 3D X-ray
structure the NOX2 NADPH binding domain (PDB ID:
3A1F) as initial template. The modeling was performed
with default parameters using the “allHmodel” protocol to
include hydrogen atoms and the “HETATM” protocol to
include FAD and NADPH. To compare the FAD and NADPH
binding interaction between wild-type (WT) and sequence
altered oxidases, the docking runs were performed
with HADDOCK.27,28 Docking was performed with most of
the parameters set to default using the Web server
version of HADDOCK with a Guru interface. To gain the
Van der Waals, electrostatic, and desolvation energy for
each enzyme - FAD or -NADPH model, HADDOCK auto-
matically performed the molecular dynamics before and
after each docking trial by including water into the
calculation (detailed modeling procedure, publication in
preparation).Cell Culture and Transfection
Model cell lines were employed as intestinal epithelial
cell lines, and primary colon cells express endogenous NOX1
and DUOX2. Cos7 cells are a suitable model system for
NOX1-based oxidase reconstitution as they lack any func-
tional NADPH oxidases, and NCI-H661 cells serve as a
physiologically relevant model for DUOX oxidases.29 Cos7
cells stably expressing p22phox 30 were maintained in Dul-
becco’s modiﬁed Eagle’s medium with 10% fetal bovine
serum; for NCI-H661 cells stably expressing DUOXA2,29
RPMI 1640 medium with 10% fetal bovine serum was
used. NOX1 was cloned into pcDNA3.1 with and without the
N-terminal Myc epitope tag including a linker sequence.
Inﬂuenza hemagglutinin (HA)-tagged DUOX2 in pcDNA3.1
was prepared by cloning the HA tag between amino acids
D27 and A28. Mutations were introduced using site-directed
mutagenesis and were veriﬁed by sequencing. NOX1 WT
and missense variants were transiently transfected with
NOXA1 and Myc-NOXO1 into Cos-p22phox cells (24 hours).
HA-tagged DUOX2 WT and missense variants were tran-
siently transfected into H661-DUOXA2 cells or together with
DUOXA2 into Cos7 cells using X-tremeGENE (Roche Applied
Science, Indianapolis, IN) (48 hours). For analysis of DUOX2
localization upon bacterial challenge, HT29 colon epithelial
cells expressing endogenous NOX1 and NOD2 were stably
transduced with lentivirus encoding for HA-tagged DUOX2
WT, DUOX2 R1211C, and DUOX2 R1492C in combination
with WT DUOXA2.
Protein Isolation and Western Blotting
Cells were lysed in radioimmunoprecipitation assay
buffer and after gel electrophoresis and blotting, mem-
branes were probed with anti-HA (Covance Laboratories,
Princeton, NJ), anti-DUOX2,31 anti-Myc (9E10), a-NOXA1,31
anti-NOX1,32 anti-p22phox FL-195 (Santa Cruz Biotech-
nology, Dallas, TX), anti-calnexin (BD Biosciences, San Jose,
CA), and horseradish peroxidase-conjugated anti-rabbit or
anti-mouse antibody (SouthernBiotech, Birmingham, AL).
Proteins were visualized using enhanced chemilumine-
scence reagent (Pierce Biotechnology, Rockford, IL).
Immunoblotting of p22phox or calnexin served as control.
ROS Assays
Superoxide production (NOX1) was measured using
luminol enhanced chemiluminescence and stimulation with
1 mg/mL phorbol 12-myristate 13-acetate (PMA) for 30
minutes.33 Luminescence was measured on a Berthold
Centro 960 LB in white 96-well plates. The chemi-
luminescence (relative light units, DRLU) readings were
standardized against cellular protein (BCA assay).
H2O2 production (DUOX2) was measured using the
homovanillic acid assay and addition of 1 mM thapsigargin.34
H2O2 production was standardized to H2O2 standard curves
and cell lysate protein concentration. Empty vector trans-
fection served as the control. For crypt ROS assays, Nox1/
mice (Jackson Laboratory, Bar Harbor, ME) were transduced
with lentivirus encoding empty vector, NOX1, NOX1 D330N,
and NOX1 P360S. Brieﬂy, the lentiviral titer was determined
Table 1.List of Variants Found in NOX1 and DUOX2 in Very Early Onset Inﬂammatory Bowel Disease Patients
Gene Variant rs #
MAF/Minor
Allele Count*
CADD Rank
Score
Age at
Diagnosis (y) Gender Diagnosis
Patient
Summary
NOX1 c.988G>A
p.P330S
Novel Novel—no data
available
0.40694 1.8 Male IBD-U Severe pancolitis
Granuloma
NOX1 c.967G>A
p.D360N
rs34688635 T ¼ 0.010/16 0.5415 5.3 Female UC Pancolitis
4.7 Male IBD-U Pancolitis
DUOX2 c.4474G>A
p.R1211C
Novel Novel—no data
available
0.90955 4.7 Male IBD-U Severe pancolitis
Colectomy,
perforation
Recurrence of
disease
DUOX2 c.3631C>Tpp.R1492C rs374410986,
Novel
Novel—no data
available
0.9002 4.3 Male UC Pancolitis
Note: CADD, Combined Annotation Dependent Depletion; DUOX2, dual oxidase 2; IBD-U, inﬂammatory bowel disease
unclassiﬁed; MAF, minor allele frequency; NOX1, NADPH oxidase 1; UC, ulcerative colitis.
*The minor allele frequencies are taken from 1000 Genomes of dbSNP.
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Biolabs, San Diego, CA), and equal amounts of each lenti-
virus were intrarectally administered to Nox1/ mice.
Crypts were isolated from the intestine of euthanized mice
24 hours after lentiviral administration.
PMA-stimulated superoxide production was mea-
sured using L-012 enhanced chemiluminescence, and stan-
dardization was performed against total crypt protein
concentration, as measured by BCA assay. ROS generation
by transduced crypts was performed in two independent
experiments (n ¼ 2–3). Animal experiments were per-
formed with ethics approval and authorization by the reg-
ulatory authority.
Flow Cytometry
H661-DUOXA2 cells expressing DUOX2 WT or variants
were incubated with anti-HA antibody (Covance Labora-
tories) in ﬂuorescence-activated cell sorting buffer on ice for
30 minutes without cell permeabilization. After incubation
with anti-mouse Alexa Fluor 647, the cells were ﬁxed in
1.5% paraformaldehyde and analyzed on an Accuri C6 ﬂow
cytometer (BD Biosciences).
Immunoﬂuorescence
Cos cells expressing Myc-NOX1 WT or variants were
treated with TAMRA-labeled Campylobacter jejuni for 15
minutes to visualize localization of NOX1 as described
elsewhere10 while DUOX2-DUOXA2-expressing H661 cells
were not stimulated. Cells were ﬁxed in 3% para-
formaldehyde, permeabilized in 0.5% Triton X-100, and
stained with anti-DUOX2 or anti-Myc antibody, followed by
goat anti-rabbit or anti-mouse Alexa Fluor 488 (Invitrogen/
Life Technologies, Carlsbad, CA). HT29 cells expressing
DUOXA2 and DUOX2 WT or missense variants were seeded
on glass coverslips and treated with 300 mL of a clinical
isolate of enteropathogenic Escherichia coli (EPEC) at optical
density OD600 ¼ 1 for 5 hours. Slides were washed, ﬁxed,
and permeabilized with 0.1% Triton X-100 and probed withantibodies against HA tag (Covance) and NOD2 (sc-30199,
kind gift by P. Moynagh, National University of Ireland
Maynooth), and 40,6-diamidino-2-phenylindole (DAPI, blue).
Images were acquired using a Zeiss LSM 700 microscope
(Carl Zeiss, Thornwood, NY) and magniﬁcation 63 (oil)
objective.
Colonic biopsies from control, disease control, and pa-
tients were ﬁxed in 10% formaldehyde without methanol,
embedded in parafﬁn, and processed for staining. Antigen
retrieval was performed using high pressure-cooking with 1
mM EDTA at a pH 9.0 containing 0.05% Tween 20. After-
ward, slides were blocked for 1 hour at room temperature
with 5% bovine serum albumin in 1x phosphate-buffered
saline (PBS) without calcium and magnesium containing
15% goat serum. Primary antibody incubation was per-
formed overnight at 4C. On the following day, the stained
slides were washed three times for 10 minutes with 1x PBS
without calcium and magnesium.
Secondary antibody incubation was performed at room
temperature and in darkness for 1 hour. Slides were washed
afterward three times for 10 minutes in darkness. Next,
nuclear counterstaining with Hoechst 33342 Fluorescence
Stain (Thermo Fisher Scientiﬁc, Waltham, MA) was per-
formed at a dilution of 1:15,000. Finally, sections were
mounted overnight with Vectorshield ﬂuorescence
mounting medium (Vector Laboratories, Burlingame, CA).
Antibodies anti-beta catenin (BD Transduction Laboratories,
BD Biosciences), anti-lysozyme (Abcam, Cambridge, MA),
anti-CD24 (Abcam), and anti-EpCAM (Sigma-Aldrich, St.
Louis, MO) were used at 1:100 dilution. Secondary anti-
bodies were Alexa ﬂuor 568 goat anti-rabbit and Alexa ﬂuor
488 goat-anti mouse (both Invitrogen/Life Technologies).
Images were acquired with an Olympus IX81 inverted
ﬂuorescence microscope (Olympus America, Center Valley,
PA) equipped with a Hamamatsu C9100-13 back-thinned
EM-CCD camera (Hamamatsu Photonics KK, Hamamatsu
City, Japan) and Yokogawa CSU X1 spinning disk confocal
scan head (Yokogawa Electric Corporation, Tokyo, Japan).
Images were adjusted for contrast and brightness using the
Table 2.Computational Analysis of NOX1 and DUOX2 Varia s
Gene Variant Chromosome Position rs#
Chromosomal
position
Minor Allele
Frequency
(dbSNP)
Minor Allele
Frequency
(1000G)
Minor Allele
Frequency
(NHLBI exome
variant
frequencies)
ExAC
v0.3 MAF SIFT
SIFT
Prediction
NOX1 P330S X 100105285 Novel c.988G>A No MAF data No MAF data No MAF data No MAF data 0.051 Tolerated
NOX1 D360N X 100105195 rs3468863 c.967G>A T¼0.010/16 (1%) T¼0.00529801 0.019881 0.018 0.042 Tolerated
DUOX2 R1211C 15 45389874 rs3744109 c.3631C>T No MAF data No MAF data A¼7.7e-05 A¼0.00004118 0 Damaging
DUOX2 R1492C 15 45386811 Novel c.4474G>A No MAF data No MAF data No MAF data A¼0.00004118 0 Damaging
Gene PolyPhen2
PolyPhen2
Prediction
Mutation
Taster
Mutation
Taster
Predictio
Mutation
Assessor
Mutation
Assessor
Prediction FATHMM
FATHMM
Prediction
LRT
Score
LRT
Prediction GERPþþ PhyloP
CADD
Rank
Score
NOX1 1 Probably
Damaging
1 Disease
Causing
3.185 Predicted
Functional
(Medium)
2.44 Tolerated 0 Deleterious 3.87 1.767 0.40694
NOX1 0.085 Possibly
Damaging
0 Polymorphis
Automat
2.225 Predicted
Functional
(Medium)
-3.09 Damaging 0.000445 Deleterious 3.87 1.767 0.54147
DUOX2 1 Probably
Damaging
1 Disease
Causing
3.37 Predicted
Functional
(Medium)
0 Deleterious 5.69 2.679 0.90955
DUOX2 1 Probably
Damaging
1 Disease
Causing
3.97 Predicted
Functional
(High)
0 Deleterious 5.68 2.838 0.9002
ExAC, Exome Aggregation Consortium; CADD, Combined nnotation Dependent Depletion; FATHMM, Functional Analysis through Hidden Markov Models; GERP,
Genomic Evolutionary Rate Proﬁling; LRT Score, likelihood r o test; MAF: Minor allele frequenct; PolyPhen2, Polymorphism Phenotyping v2; SIFT, Scale-invariant feature
transform.
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September 2015 NOX1 and DUOX2 variants in VEOIBD 495Volocity version 6.1.1 software (PerkinElmer Life and
Analytical Sciences, Waltham, MA).
Virulence Assay
Adherence and invasion of C. jejuni 81-176 were
assessed in NOX1 complex or DUOX2-DUOXA2 expressing
Cos7 cells using the gentamicin protection assay.35 Plate
grown C. jejuni 81-176 was washed and resuspended in
tissue culture medium at OD600¼ 0.4 and added at mul-
tiplicity of infection 1000 to cells, followed by centrifu-
gation at 250g for 5 minutes. After incubation for 3 hours
at 37C, the nonadherent and cell-associated bacteria were
collected. For invasion, the infected and washed mono-
layers were incubated further with and without genta-
micin (400 mg/mL) and incubated for an additional 2
hours at 37C. The cells were lysed by the addition of
0.1% Triton X-100 in PBS for 10 minutes at 37C. Bacterial
counts for each assay were enumerated by serial dilution
plating. All parameters were calculated as the average of
the total number of colony-forming units/total initial
inoculum.
Statistical Analysis
All functional experiments were conducted in triplicate
with three repeats (n ¼ 3), followed by an unpaired Stu-
dent’s t test.
Results
Identiﬁcation of NOX1 and DUOX2 Variants
in VEOIBD
NOX1 and DUOX2 missense mutations were identiﬁed in
ﬁve of 59 VEOIBD patients (age 6 years). All ﬁve patients
presented with pancolitis without small bowel or perianal
disease at diagnosis. None of the patients had systemic
disease including thyroid disease or chronic infections,
suggesting that defects were conﬁned to the intestinal
epithelium. SNPs and insertion/deletion variants were
conﬁrmed using Sanger sequencing and analyzed for po-
tential function. Exon sequencing (Table 1–2) identiﬁed a
novel NOX1 variant (c.988G>A; p.P330S) in one male pa-
tient. Another rare variant (c.967G>A; rs34688635;
p.D360N) was found in one male and one female patient.
The missense variant NOX1 p.P330S is potentially damaging
(Polyphen2 score: 0.995) and unique according to the
Washington Exome Variant Server, while NOX1 p.D360N
was predicted to be “probably damaging” by PolyPhen2 and
was given a maximum evolutionary conservation score of 1
by the PhastCons program using 46 mammalian species.Figure 1. (See previous page). Characterization of selected
colonic biopsy samples from an inﬂammatory bowel disease (IB
D360N variant, and a patient with the DUOX2 R1211C varia
inﬂammation, increased cellularity of inﬂammatory cells adjacen
shows severe colitis with architectural distortion (crypt damag
Paneth cell markers lysozyme and CD24 in colonic biopsy samp
and nuclei (blue). Lysozyme was expressed in the crypts of th
control. CD24 is expressed in colonic crypts in the IBD control a
the healthy control nor the patient with the NOX1 variant. ScaleVariants in DUOX2 were also identiﬁed in VEOIBD patients
(Table 1–2). One of the patients was heterozygous for
DUOX2 p.R1211C (c.4474G>A) and developed severe dis-
ease that necessitated colonic resection. The disease sub-
sequently recurred at the resection site, a ﬁnding consistent
with Crohn’s disease. The second variant was detected in a
very early onset UC patient heterozygous for DUOX2
p.R1492C (c.3631C>T; rs374410986), who presented with
pancolitis.
In an independent replication cohort of 150 VEOIBD pa-
tients, none of the NOX1 and DUOX2 missense variants were
identiﬁed. Similarly, in the publicly available International
IBD Genetics Consortium (http://www.ibdgenetics.org)
database none of the NOX1 and DUOX2 missense variants
were identiﬁed as this data set does not examine rare vari-
ants, only common polymorphisms, and the p.Asp360Asn
variant is not analyzed by the immunochip.
Therefore, we took an alternate approach employing an
array-based genotyping using the Illumina HumanExome
v1.0 platform of 1477 Crohn’s disease (CD) cases, 559 UC
cases, and 2614 healthy controls, all with genetically veri-
ﬁed Ashkenazi Jewish (AJ) ancestry by principal compo-
nents analysis. Using this approach we detected an
association between D360N NOX1 and male AJ UC (MAFcase .
3.37%, MAFcontrol . 0.82%; odds ratio 4.22; P ¼ 1.25 
103). The association was not detected in either of the
female AJ UC cases (MAFcase ¼ 1.53%, MAFcontrol ¼ 0.99%;
odds ratio 1.55; P ¼ .343), although the trend was in the
same direction as observed in the AJ males cases. However,
this trend was not observed in Crohn’s disease cases
(MAFCD ¼ 0.97%). The ﬁnding in an adult UC cohort sug-
gests that pathways/processes involved in VEOIBD will
have implications for adult IBD patients.
Histologic Analysis of NOX1/DUOX2 Variants
Histopathology analysis using HE and PAS staining
(Figure 1A) was performed in biopsies from patients with
the identiﬁed DUOX2 p.R1211C variant as well as a patient
with the NOX1 p.D360N variant and compared with the
healthy control and an IBD control biopsy. The disease
control showed features of chronic and regenerative IBD,
demonstrated by metaplastic Paneth cells within colonic
crypts. The patient with the NOX1 p.D360N variant showed
focal inﬂammation, increased cellularity of inﬂammatory
cells adjacent to normal areas of unaffected colonic mucosa.
The patient with the DUOX2 p.R1211C variant demon-
strated more severe morphologic changes, with severe
inﬂammation and crypt damage in the colonic mucosa when
compared with the NOX1 variant.patient biopsies. (A) HE and periodic acid–Schiff staining of
D) control (Paneth cell metaplasia), a patient with the NOX1
nt. The patient with the NOX1 D360N variant shows focal
t to normal area. The patient with the DUOX2 R1211C variant
e). Scale bar: 20 mm. (B) Immunoﬂuorescence analysis with
les: lysozyme and EpCAM (red), b-catenin and CD24 (green),
e patients as well as the IBD control, but not in the healthy
nd the patient with the DUOX2 R1211C variant, but neither in
bar: 10 mm.
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colonic biopsy samples to determine whether Paneth cell
metaplasia, a feature of chronic and regenerative change
as a consequence of continuous inﬂammation within the
colon, has occurred. Both markers, lysozyme and CD24,
were highly positive in metaplastic Paneth cells of colonic
crypt enterocytes in the disease control (see Figure 1B).
Altered NOX1 appears not to progress cells into full
metaplasia as seen by the absence of CD24 within crypt
cells of the patient harboring NOX1 p.D360N. In colonic
crypts of the patient with the DUOX2 p.R1211C variant,
both lysozyme and CD24 were expressed, albeit not as
prominent as observed within metaplastic Paneth cells in
the IBD control.
Topologic Models of NOX1/DUOX2 Variants
The NOX1 NADPH oxidase is formed by hetero-
dimerization of NOX1 with p22phox, followed by assembly
with the regulatory proteins NOXO1, NOXA1, and Rac1-
GTP.8 The cytosolic carboxyl terminus of NADPH oxidases
harbors NADPH and FAD-binding regions, which are
required for electron transport across the membrane via
hemes where molecular oxygen is reduced to form super-
oxide. The identiﬁed NOX1 variants are located either just in
front of FAD1 (p.P330S) or inside FAD2 (p.D360N)
(Figure 2A). Pro330 and Asp360 are conserved in NOX1–4
proteins identiﬁed in vertebrates and lower organisms.36
CYBB missense variants (X-CGD) leading to loss or dimin-
ished ROS generation in neutrophils are located in close
vicinity to the identiﬁed NOX1 variants (http://bioinf.uta.ﬁ/
CYBBbase).37 Modeling of NOX1 WT, NOX1 (p.P330S), or
NOX1 (p.D360N) dehydrogenase domains was performed
by combining the crystal structures of FAD-binding domains
homologous to the NOX FAD with the partial structure of the
dehydrogenase domain of NOX2 in the correct orientation
(see Figure 2B).
FAD and NADPH were docked to each NOX/DUOX model
by using HADDOCK. FAD binds to NOX1 WT mainly with
electrostatic interaction to His339 in the FAD1 domain and
Asp360 in the FAD2 domain. Based on the model, Pro330
will be important for stabilization of the antiparallel
b-structure that creates the FAD1 domain. Although Pro330
is not directly involved in FAD binding, the change
Pro330Ser in NOX1 alters the position of His339 in the FAD1
domain, which decreases binding afﬁnity of this variant for
FAD.
The second NOX1 residue altered in VEOIBD, Asp360, is
directly involved in FAD binding, and therefore a change toFigure 2. (See previous page). Modeling and functional chara
NOX1 very early onset inﬂammatory bowel disease (VEOIBD) v
conserved residues boxed (blue). (B) Three-dimensional model
D360N (pink) dehydrogenase domains. NADPH, FAD, residue H
NOX1 WT and variants. (D) Protein expression of NOX1 and varia
ROS production in murine Nox1/ crypts transduced with NO
stimulation was at 200 seconds. (F) Localization of Myc-NOX1
Scale bar: 10 mm; arrow indicates membrane localization. (G
expressing NOX1 WT, P330S, or D360N. Error bars ± standard
NOX1 WT to variants.asparagine (D360N) weakens the interaction between FAD
and NOX1. FAD binds to NOX1 with binding afﬁnity in mM
range; therefore, we predict that small structural changes in
both FAD domains will compromise catalytic activity of the
NOX1 enzyme. Debeurme et al38 reported disrupted FAD
binding and diminished catalytic activity of NOX2 in
selected CYBB variants.Functional Characterization of NOX1 Variants
As structural analysis predicts that the catalytic activity
of NOX1 variants will be compromised, we reconstituted WT
and altered NOX1 complexes in an epithelial model cell
system (Cos7) deﬁcient in all NOX/DUOX isoforms. Both
NOX1 p.P330S and NOX1 p.D360N variants displayed
diminished catalytic activity (see Figure 2C). Basal and
phorbol ester-stimulated ROS generation was signiﬁcantly
reduced for NOX1 missense variants (50%–60%), while the
overall protein expression was comparable to WT NOX1
(see Figure 2D).
As patients could not be recalled for colon tissue eval-
uation, catalytic activity of NOX1 variants was also
measured in a murine in vivo expression setting. Nox1
knockout mice were transduced with lentivirus encoding
NOX1 WT and variants intrarectally, and ROS generation of
isolated crypts was recorded 24 hours later. Similar to the
results obtained in cell lines, ROS production in the crypts
was reduced in the NOX1 variants when compared with
NOX1 WT (see Figure 2E).
A reduction in epithelial ROS production will attenuate
host protection from intestinal pathogens. Defective pro-
cessing of responses to mucosal bacteria is recognized to
play a central role in the development and perpetuation of
intestinal inﬂammation in IBD. C. jejuni in particular has
been associated with the initiation of IBD.39 C. jejuni up-
take was used to visualize infection-associated trans-
location of NOX1 to membrane rufﬂes and to assess the
antibacterial response.10 Stimulated membrane localiza-
tion of NOX1 WT and NOX1 variants (NOX1 p.D360N
shown) were comparable (see Figure 2F), but reduced
ROS generation caused a 10-fold increase in bacterial in-
vasion when cells harbored the NOX1 p.P330S or NOX1
p.D360N variants with reduced catalytic activity (see
Figure 2G).Functional Characterization of DUOX2 Variants
Inactivating mutations in DUOX2 or DUOXA2 have been
linked to inherited permanent or transient congenitalcterization of NOX1 variants. (A) Topologic model depicting
ariants (red), selected X-CGD CYBB (NOX2) variants (green),
of NOX1 wild-type (WT) (grey), NOX1 P330S (green), or NOX1
339, and variant positions are marked. (C) ROS production by
nts, Myc-NOXO1, NOXA1, and p22phox as loading control. (E)
X1 WT or variants. Phorbol 12-myristate 13-acetate (PMA)
WT or D360N (green) in C. jejuni (red) infected Cos-p22 cells.
) Adhesion and invasion of Campylobacter jejuni in cells
deviation n ¼ 3; *P  .05; **P  .01; ****P  .0001; comparing
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have been described in this context (HGMD, www.hgmd.cf.
ac.uk/ac/gene) (Figure 3A). The two VEOIBD-associated
DUOX2 variants are novel; in contrast to most of the re-
ported DUOX2 variants, they are not located in the peroxi-
dase homology domain or the EF hand regions. DUOX2
p.R1211C is placed in a polybasic region within an intra-
cellular loop, and Arg1492 in DUOX2 is an integral part of
the highly conserved GRP sequence in the NADPH3 domain
(see Figure 3A).
As described for NOX1, the dehydrogenase domains of
DUOX2 WT and DUOX2 p.R1492C were modeled onto the
extended NOX2 structure; by use of HADDOCK, NADPH and
FAD were docked to the structure (see Figure 3B). Struc-
tural analysis revealed that Arg1492 is part of the NADPH-
binding pocket. NADPH binds to DUOX2 WT with strong
electrostatic interactions to the residues Arg1421 and
Arg1492 with a sum of 181.7 ± 76.4 kcal/mol and with
weak Van der Waals interactions to Gly1385, Thr1463,
Pro1520, Gly1521, and Met1520 with a sum of 30.9 ± 7.8
kcal/mol. Replacing Arg1492 with cysteine as in the
DUOX2 p.R1492C variant does not change the DUOX2
structure or the position of other NADPH-interacting resi-
dues. However, the change is predicted to weaken the
interaction between NADPH and DUOX2 by a factor of 2.
How replacement of Arg1221 with cysteine will directly
affect DUOX2 catalytic activity cannot be predicted because
suitable structures for modeling do not exist, but in both
NOX2 and NOX4 the analogous D loop participates in ROS
production.41,42
Functional analysis of DUOX2 variants was performed
in the H661 cellular model system that represents a
physiologic context for DUOX-DUOXA expression and is
devoid of NOX1–5 activity.29 Both DUOX2 variants, when
coexpressed with their dimerization partner DUOXA2,
produced signiﬁcantly less H2O2 than WT DUOX2 (see
Figure 3C), although protein expression and cellular
localization were not altered (see Figure 3D and E). DUOX2
has been functionally associated with NOD2 in transient
overexpression conditions.43 HT29 colonic cells express
endogenously a functional NOX1 complex and NOD2, and
thus provide an appropriate context for analysis of puta-
tive DUOX2-NOD2 interactions.
DUOX2 or DUOX2 variants together with DUOXA2 were
stably incorporated into HT29 cells, followed by exposure to
enteropathogenic E. coli. DUOX2 WT or variants, localized
on internal membrane structures before the challenge,
translocated to the plasma membrane and cell-cellFigure 3. Modeling and functional characterization of DUOX
onset inﬂammatory bowel disease (VEOIBD) variants (red), sele
residues boxed (blue). (B) Three-dimensional model of DUOX2 w
domain. NADPH, FAD, and variant position are marked. (C) H2O2
HA-DUOX2 WT and variants; calnexin served as loading contro
cytometry (left) and localization by immunoﬂuorescence (right)
and invasion of C. jejuni in cells expressing HA-DUOX2 WT, R12
.05; **P  .01; ***P  .001; ****P  .0001; comparing DUOX2 Wjunctions. NOD2, on the other hand, remained in the intra-
cellular compartment, albeit NOD2 protein expression was
up-regulated (Figure 4). Thus, DUOX2 and NOD2 were not
recruited simultaneously upon E. coli challenge.
Stimulated H2O2 release in DUOX2 WT or variant-
expressing HT29 cells mirrored the results obtained with
H661 cells (data not shown). DUOX2-mediated H2O2 release
at apical membranes has been linked to antimicrobial host
defense and decreased C. jejuni virulence.10 Comparison of
C. jejuni invasion in DUOX2 WT or DUOX2 variant-
expressing (DUOX2 p.R1211C, DUOX2 p.R1492C) epithelial
cells showed increased invasion when ROS generation was
diminished (see Figure 3F).Discussion
We have identiﬁed inactivating missense variants in each
of the epithelial NADPH oxidases NOX1 (p.P330S, p.D360N)
and DUOX2 (p.R1211C, p.R1492C) in ﬁve VEOIBD patients.
Variants in X-linked NOX1 were found in two male VEOIBD
patients, and NOX1 p.D360N was associated with male UC in
an AJ ancestry case-control cohort, likely leading to
increased or sustained disease severity.
The identiﬁcation of rare functional variants contrib-
uting to the pathogenesis of VEOIBD has been observed with
other genes, including the NOX2 NADPH oxidase complex,7
NOS2,44 IL10R,15 and XIAP.45,46 The variants we identiﬁed
in both NOX1 and DUOX2 are rare and not found in a
replication VEOIBD cohort or data sets of common variants.
However, all variants showed both pathologic and func-
tional defects, indicating that these variants may contribute
to disease susceptibility or pathogenesis. Further large-scale
sequencing of pediatric- and adult-onset IBD may indicate a
broader role of both NOX1 and DUOX2 in IBD pathogenesis,
as observed in our AJ population.
Recently, altered DUOX2 expression was identiﬁed in
ileum biopsies from pediatric Crohn’s disease patients.47
Further, ROS derived from NADPH oxidases is critical to
control mucin granule accumulation in colonic goblet
cells,12 and NOX1 has been shown to control the balance
between goblet and absorptive cell types in murine colon.48
Interestingly, colonic biopsies from patients carrying either
NOX1 p.D360N or DUOX2 p.R1211C variants showed
abnormal CD24 and lysozyme expression (see Figure 1B),
suggesting a role for these proteins in Paneth cell
metaplasia.
The thyroid function of the two male VEOIBD patients
harboring DUOX2 mutations was normal, although2 variants. (A) Topologic model depicting DUOX2 very early
cted DUOX2 hypothyroidism variants (black), and conserved
ild-type (WT) (grey) and DUOX2 R1492C (pink) dehydrogenase
release by DUOX2 WT and variants. (D) Protein expression of
l. (E) HA-DUOX2 WT and variant surface expression by ﬂow
(green, arrow for membrane). Scale bar: 10 mm. (F) Adhesion
11C, or R1492C. Error bars ± standard deviation, n ¼ 3; *P 
T with variants.
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variants have been linked to hypothyroidism.49 In contrast to
adult onset IBD, VEOIBD frequently encompasses a unique
clinical presentation, with severe disease limited to the colon
and with poor response to standard therapies.24 VEOIBD
variants (NCF2,50 NOS2,44 IL10RA/B,15 TTC7A51) have usu-
ally been rare, suggesting that these patients may have a
unique genetic susceptibility. Furthermore, we have recently
shown that SNPs and rare variants in all components of the
NOX2 NADPH oxidase complex are associated with VEOIBD.7
Similar to our recent observations with NOX2 NADPH oxi-
dase complex variants leading to decreased ROS production
in neutrophils,7 reduced mucosal ROS levels originating from
NOX1 and DUOX2 variants play also a role in susceptibility to
VEOIBD and perhaps other severe IBD phenotypes.
Intestinal NADPH oxidases connect to antibacterial
autophagy and endosomal pathways important for mucus
secretion and may modulate the interplay between
commensal bacteria and pathogens.12,13 Recent microbiome
studies on a large pediatric cohort with new-onset Crohn’s
disease assigned a unique role to changes in the rectal
mucosal microbiota for disease classiﬁcation.52 Changes in
ROS generation at the mucosal surface will most likely
result in dysbiosis, intestinal inﬂammation, and pathobiont
development. Our functional studies provide strong support
both for the pathogenic nature of the mutations identiﬁed in
these VEOIBD patients and the role of epithelial ROS in
protecting cells from bacterial attack.
Further phenotypic exploration of NOX/DUOX variants
will be aided by studies in humans and improved animal
models, as current IBD animal models seem often not to
reﬂect human disease triggered by reduced ROS. For
example, murine Cybb (Nox2) deﬁciency does not lead to
spontaneous Crohn’s disease-like intestinal disease and gut
inﬂammation, both observed in many CGD patients.
Although Cybb knockout mice exhibit several hallmarks of
CGD upon fungal or bacterial challenge, they were slightly
protected in the dextran sodium sulfate–induced colitis
mouse model.53 Similarly, Nox1 deﬁciency in the murine
mucosa did not alter dextran sodium sulfate–colitis pa-
thology,54 although combined Nox1 and Il10 deﬁciency
caused spontaneous colitis in mice.55 Mice harboring an
inactivating Duox2 variant or Duoxa deﬁciency showed
severe hypothyroidism and increased colonization with
Helicobacter felis.11,56
In conclusion, our ﬁndings demonstrate that novel NOX1
and DUOX2 NADPH oxidase variants resulting in attenuated
ROS production and impaired mucosal defense occur in
children with VEOIBD. This may inﬂuence IBD pathogenesis
beyond childhood.Figure 4. Bacteria-induced translocation of DUOX2 and
variants does not involve NOD2 in colonic cells. HT29 cells
stably expressing DUOX2 WT, DUOX2 R1211C, and DUOX2
R1492C were exposed to enteropathogenic Escherichia coli
(EPEC) for 5 hours. Immunoﬂuorescence images of DUOX2
(green), NOD2 (red), and nuclei (blue). Scale bar: 15 mm.
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